Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 12/20 | 0.76 |
| ▸ | PRKCB | P05771 | 11/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 9/20 | 0.76 |
| ▸ | PRKCH | P24723 | 7/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 7/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.76 |
| ▸ | CDK2 | P24941 | 3/20 | 0.76 |
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991947 | 0.86 | PRKCA (1.00) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL3581634 | 0.84 | PRKCA (1.00) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL13063996 | 0.81 | PRKCA (0.75) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL3546333 | 0.80 | PRKCA (0.85) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL13092897 | 0.80 | PRKCA (0.73) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL3543104 | 0.79 | PRKCA (0.83) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL3541294 | 0.79 | PRKCA (1.00) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL3538925 | 0.77 | PRKCA (1.00) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL8160500 | 0.76 | GSK3B (0.73) | PRKCAPRKCBPRKCDPRKCHPRKCE | |
| SCHEMBL8167952 | 0.76 | GSK3B (0.81) | PRKCAPRKCBPRKCDCDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1904482-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | IDO1, INMT, IDO2 | PRKCA 2904/4885PRKCB 2179/4885PRKCD 1999/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | PRKCA 4227/4885PRKCB 3243/4885PRKCD 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.